December newsletter in 60 seconds

The battle between innovative pharma companies and generic drug rivals is a constant source of interest for readers of Life Sciences Intellectual Property Review. Although the nature of these disputes is typically identical, their commercial importance for both sides is extremely high. That means, from a practical viewpoint, our coverage of the age-old rows will continue to be useful.